Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients

Recruiting now · Phase 3

Conditions studied: Cytomegalovirus Infections, Kidney Transplant Infection, Pancreas Transplant

In brief

This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney/pancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.

Key facts

Study ID

NCT06407232

Run by

University of Wisconsin, Madison

People needed

90

Starts

2024-08-08

Expected to finish

2027-08-01

Last updated by the study team

2026-06-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• undergone kidney or simultaneous kidney/pancreas transplant
• high-risk CMV serostatus (D+/R-) at time of transplant
• develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)
• demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening
• able to provide informed consent to participate

You may not qualify if…

• contraindication to letermovir or its excipients
• develop ganciclovir-resistant CMV infection
• currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent
• unable or unwilling, in the opinion of the Investigator, to comply with the protocol
• pregnant or breastfeeding

Where it is running

• UW Hospital and Clinics — Madison, Wisconsin, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.